Post has attachment
OREGON CALL TO ACTION!

The state of Oregon Health Authority Health Evidence Review Commission (HERC) recently released proposed guidance to not provide coverage for the use of FDA-Approved Next Generation Sequencing (NGS) tests for cancer patients in the state with Medicaid.

LUNGevity Foundation and Caring Ambassadors are seeking volunteers, both lung cancer survivors and health care professionals, who live in the state of Oregon, to provide testimony at a public meeting from 1:00pm-4:00pm on this issue scheduled for September 27, 2018 in Wilsonville, Oregon. Ideal testimony would be provided by survivors who have received NGS, or other comprehensive biomarker testing, to guide their treatment and by health care professionals who order, consult, or care for patients who have received NGS, or other comprehensive biomarker testing.

For those who cannot attend the meeting, Oregon will accept testimony via email up to 2 days prior to the hearing. Click here for more information and instructions.

Post has attachment
Drs. Kellie Smith, Jeffrey Thompson, and Edwin Yau receive prestigious LUNGevity 2018 Career Development Awards. These awards support exceptional young researchers to advance the field of lung cancer research. Read more: https://lungevity.org/about-us/media-resources/media-releases/drs-kellie-smith-jeffrey-thompson-and-edwin-yau-receive
Photo

Post has attachment
In the latest LUNGevity Experts Blog, Kylie Buchan, RD, CSO, reviews why protein is important, what foods are high in protein, and shares tips for getting enough protein while undergoing lung cancer treatment. Read more:

Post has attachment
After having surgery and finding a community of support through LUNGevity and CSC, Yovana is pursuing her goal of running a marathon with Team LUNGevity. Read more:

Post has attachment
Rachael is sharing her empowering story to encourage others to believe in those battling lung cancer because, "we are strong, we are worth the fight, and we too deserve the best life possible." Read more:

Post has attachment
Attending National HOPE Summit strengthened Austin's passion to make a difference in the field of lung cancer by becoming a thoracic oncologist. Read more:

Post has attachment
Jennifer Kashatus, a long-term privacy and cybersecurity professional and partner at DLA Piper LLP, has joined the Board of Directors. Kashatus brings an indispensable perspective from an industry new to LUNGevity’s board while offering her expertise to further LUNGevity’s work of changing outcomes for people with lung cancer. Read more:

Post has attachment
Rachael, a former Olympic athlete and member of the military, was just 31 when she was diagnosed with stage IV lung cancer. Her journey has inspired her to become an advocate for others. Read part one of her story:

Post has attachment
LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today that Nicole (Nikki) Martin, a longtime healthcare and diagnostic professional, joined the Foundation as the Director of LUNGevity’s Precision Medicine Initiatives. Read more:

Post has attachment
LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is pleased to announce the publication of recommendations that will create more opportunities for patients to participate in potentially lifesaving clinical trials. The Foundation’s manuscript “Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria” appears in the current issue of the esteemed medical journal, the Journal of Thoracic Oncology (JTO). The article, which was co-authored by members of the Expanded Eligibility working group of the LUNGevity Scientific and Clinical Roundtable initiative, provides recommendations for expanding overly restrictive eligibility criteria in clinical trials.

Previously, the exclusions in eligibility criteria for clinical trials prevented as many as 50% of lung cancer patients from participating as part of trials. The Foundation’s recommendations, which include expanding criteria around brain metastases, history of previous malignancies, and reduced performance status, intend to enable more lung cancer patients to have access to innovative therapies.

“As a Foundation, we have been working with multiple stakeholders to create clinical trials that are effective and accessible to more patients,” Andrea Ferris, President and CEO of LUNGevity, says. “New options in lung cancer treatment are evolving rapidly, and patients need to be able to access them. The publication is a big step toward our goal of expanding clinical trial eligibility, and one that can potentially benefit a lot of lung cancer patients.”

Read more: https://lungevity.org/about-us/media-resources/media-releases/lungevity-takes-step-forward-in-clinical-trial-eligibility
Photo
Wait while more posts are being loaded